학술논문
SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021
Document Type
article
Author
Anthony Nardone; Jesse Papenburg; Marta Valenciano; Hude Quan; Maria D Van Kerkhove; Didier K Ekouevi; Tyler Williamson; Shobna Sawry; Xiaomeng Ma; Ambrose Talisuna; Thierno Balde; Ines Vigan-Womas; David Buckeridge; Halidou Tinto; Michael Liu; Tingting Yan; Matthew P Cheng; Joseph Okeibunor; Samiratou Ouedraogo; Francine Ntoumi; Cheikh Talla; David Clifton; Tiffany G Harris; Ayôla A Adegnika; Lorenzo Subissi; Laura Steinhardt; Niklas Bobrovitz; Isidore T Traore; Timothy G Evans; Judy Chen; Cedric P Yansouni; Cheryl Cohen; Jason M Mwenda; Nsenga Ngoy; Hannah C Lewis; Harriet Ware; Mairead Whelan; Zihan Li; Brianna Cheng; Kim Noel; Christian Cao; Mercedes Yanes-Lane; Belinda L Herring; Rahul K Arora; Isabel Bergeri; Rafiou Adamou; Samira Z Assoumou; Rosemary A Audu; Jacob S Barnor; Enyew Birru; Henry K Bosa; Emily L Boucher; Annie Chauma-Mwale; Tienhan S Dabakuyo-Yonli; Gabriel Deveaux; Boly Diop; Titus H Divala; Emily K Dokubo; Irene O Donkor; Claire Donnici; Nathan Duarte; Natalie A Duarte; Paulin N Essone; Lee Fairlie; Ousmane Faye; Anne von Gottberg; Natasha Ilincic; Elsie A Ilori; Jackie Kleynhans; Dayoung Kim; Olatunji M Kolawole; Jambo C Kondwani; Emma Loeschnik; Sheila Makiala-Mandanda; Alexandre Manirakiza; Pinyi N Mawien; Portia C Mutevedzi; Edgard B Ngoungou; Eric M Osoro; Sandrine L Oyegue; Sara Perlman-Arrow; Hannah P Rahim; Karampreet Sachathep; Mitchell Segal; Anabel Selemon; Judith Shang; Joel F Djoba Siawaya; Kristen A Stafford; Joe A Theu; Caseng Zhang
Source
BMJ Global Health, Vol 7, Iss 8 (2022)
Subject
Language
English
ISSN
2059-7908
Abstract
Introduction Estimating COVID-19 cumulative incidence in Africa remains problematic due to challenges in contact tracing, routine surveillance systems and laboratory testing capacities and strategies. We undertook a meta-analysis of population-based seroprevalence studies to estimate SARS-CoV-2 seroprevalence in Africa to inform evidence-based decision making on public health and social measures (PHSM) and vaccine strategy.Methods We searched for seroprevalence studies conducted in Africa published 1 January 2020–30 December 2021 in Medline, Embase, Web of Science and Europe PMC (preprints), grey literature, media releases and early results from WHO Unity studies. All studies were screened, extracted, assessed for risk of bias and evaluated for alignment with the WHO Unity seroprevalence protocol. We conducted descriptive analyses of seroprevalence and meta-analysed seroprevalence differences by demographic groups, place and time. We estimated the extent of undetected infections by comparing seroprevalence and cumulative incidence of confirmed cases reported to WHO.PROSPERO: CRD42020183634.Results We identified 56 full texts or early results, reporting 153 distinct seroprevalence studies in Africa. Of these, 97 (63%) were low/moderate risk of bias studies. SARS-CoV-2 seroprevalence rose from 3.0% (95% CI 1.0% to 9.2%) in April–June 2020 to 65.1% (95% CI 56.3% to 73.0%) in July–September 2021. The ratios of seroprevalence from infection to cumulative incidence of confirmed cases was large (overall: 100:1, ranging from 18:1 to 954:1) and steady over time. Seroprevalence was highly heterogeneous both within countries—urban versus rural (lower seroprevalence for rural geographic areas), children versus adults (children aged 0–9 years had the lowest seroprevalence)—and between countries and African subregions.Conclusion We report high seroprevalence in Africa suggesting greater population exposure to SARS-CoV-2 and potential protection against COVID-19 severe disease than indicated by surveillance data. As seroprevalence was heterogeneous, targeted PHSM and vaccination strategies need to be tailored to local epidemiological situations.